We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Rheumatology

Journal Scan / Research · May 27, 2021

Continuing Versus Withdrawing Ixekizumab Treatment in Patients With Axial Spondyloarthritis Who Achieved Remission

Annals of the rheumatic diseases

 

Additional Info

Annals of the rheumatic diseases
Continuing Versus Withdrawing Ixekizumab Treatment in Patients With Axial Spondyloarthritis Who Achieved Remission: Efficacy and Safety Results From a Placebo-Controlled, Randomised Withdrawal Study (COAST-Y)
Ann. Rheum. Dis 2021 May 06;[EPub Ahead of Print], RB Landewé, LS Gensler, D Poddubnyy, P Rahman, M Hojnik, X Li, S Liu Leage, D Adams, H Carlier, F Van den Bosch,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading